CSIMarket
 
Hutchmed china Limited  (NASDAQ: HCM)
Other Ticker:  
 
 
Price: $15.7100 $-1.19 -7.041%
Day's High: $16.1 Week Perf: -6.71 %
Day's Low: $ 15.64 30 Day Perf: 18.12 %
Volume (M): 65 52 Wk High: $ 21.50
Volume (M$): $ 1,027 52 Wk Avg: $16.45
Open: $16.01 52 Wk Low: $11.51



 Market Capitalization (Millions $) 13,712
 Shares Outstanding (Millions) 873
 Employees 467
 Revenues (TTM) (Millions $) 630
 Net Income (TTM) (Millions $) 38
 Cash Flow (TTM) (Millions $) -256
 Capital Exp. (TTM) (Millions $) 18

Hutchmed China Limited
Hutchmed China Limited, commonly known as Hutchison China MediTech, is a biopharmaceutical company headquartered in Hong Kong, China. The company is primarily focused on discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and other medical conditions.

Hutchmed was established in 2000 as a subsidiary of Hutchison Whampoa Limited, a multinational conglomerate. In 2016, Hutchmed was spun off as an independent, publicly traded company listed on the Hong Kong Stock Exchange, raising approximately $100 million in the process.

The company's oncology portfolio consists of several late-stage clinical programs, including sulfatinib, a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), which is being developed for the treatment of advanced neuroendocrine tumors (NETs) and biliary tract cancer (BTC). Hutchmed also has several non-oncology programs, including a late-stage clinical program for the treatment of hyperuricemia and gout.

With a focus on precision medicine, the company aims to develop targeted therapies that can more effectively treat patients while reducing the risk of side effects. Hutchmed has established collaborations with leading academic institutions and pharmaceutical companies in China and internationally to advance its innovative drug discovery and development programs.

Hutchmed has a strong presence in China and has established a commercial infrastructure to support the launch of new products. The company currently has more than 600 employees, including over 200 scientists and researchers working in its R&D facilities in Shanghai, China.

In addition to its drug discovery and development programs, Hutchmed is committed to supporting cancer patients and their families. The company has launched several patient assistance programs in China to provide financial assistance and emotional support to cancer patients.

Overall, Hutchmed is a leading biopharma company with a strong focus on innovative drug discovery and development programs in oncology and other medical areas. The company's dedication to precision medicine and patient-centered care has made it a significant player in the rapidly growing global biopharmaceutical industry.


   Company Address: 48th Floor, Cheung Kong Center Central 0
   Company Phone Number: 2121 8200   Stock Exchange / Ticker: NASDAQ HCM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADCT        0.28% 
BMY   -5.84%    
BPMC   -0.01%    
MRK   -2.54%    
ONC        2.22% 
ZLAB   -10.1%    
• View Complete Report
   



Product Service News

Strategic Advancements in Oncology HUTCHMED and Innovents Fruquintinib-Sintilimab Combination Receives NDA Acceptanc...

Published Thu, Jun 5 2025 10:40 AM UTC

HUTCHMED (China) Limited, in collaboration with Innovent Biologics, Inc. has announced the acceptance of their New Drug Application (NDA) by the China National Medical Products Administration (NMPA) for the combination therapy involving fruquintinib and sintilimab. This therapy targets patients with locally advanced or metastatic renal cell carcinoma who have not responded t...

Product Service News

HUTCHMED Unveils Promising Cancer Therapeutics at AACR 2025,

Published Thu, Apr 24 2025 7:19 AM UTC

HUTCHMED to Showcase Groundbreaking Data at AACR Annual Meeting 2025 HONG KONG, SHANGHAI, and FLORHAM PARK, N.J. April 24, 2025 HUTCHMED (China) Limited, a biopharmaceutical company specializing in the development of innovative cancer therapies, has announced plans to present new and updated data from its research portfolio at the upcoming American Association of Cancer Re...

Clinical Study

Promising Advances in Lung Cancer Treatment HUTCHMED?s Savolitinib and Recent Developments

Published Thu, Mar 20 2025 9:27 AM UTC

The quest for innovative treatments in oncology is ever-evolving, and recent data presented by HUTCHMED during key oncology congresses showcases significant advancements in lung cancer therapies, particularly in tackling MET-amplified non-small cell lung cancer (NSCLC). This article interprets the findings from the European Lung Cancer Congress 2025 and recent developments ...

Clinical Study

Bridging Innovation and Market Dynamics Fruquintinib and Sintilimab Combination Shows Promise in Renal Cell Carcinoma...

Published Wed, Mar 19 2025 7:48 AM UTC

Efficacy and Market Dynamics: Fruquintinib and Sintilimab Combination Achieves Success in Advanced Renal Cell Carcinoma Study In a significant development for oncological therapies, HUTCHMED and Innovent Biologics have announced that their joint Phase II/III clinical trial FRUSICA-2 for the combination of Fruquintinib and Sintilimab has met its primary endpoint in treating a...

Management Announcement

HUTCHMEDs ORPATHYS Approval: A Game-Changer for NSCLC Treatment Amidst Financial Resurgence

Published Tue, Jan 14 2025 4:00 AM UTC

ArticleIn a defining moment for lung cancer treatment in China, HUTCHMED (China) Limited has secured full approval from the National Medical Products Administration (NMPA) for its groundbreaking drug ORPATHYS (savolitinib). This approval specifically targets patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who possess MET Exon 14 alterations. ...







Hutchmed China Limited's Segments
Third parties    99.31 % of total Revenue
Related parties    0.69 % of total Revenue
Invoiced Goods-Marketed Products    20.31 % of total Revenue
Invoiced Goods-Distribution    42.34 % of total Revenue
Services-Commercialization of Marketed Products    8.33 % of total Revenue
Services-Commercialization of Marketed Products Third parties    8.33 % of total Revenue
Services-Research and development    0.07 % of total Revenue
Services-Research and development Related parties    0.07 % of total Revenue
License Collaborations-Services    9.2 % of total Revenue
License Collaborations-Services Third parties    9.2 % of total Revenue
License Collaborations-Royalties    11.27 % of total Revenue
License Collaborations-Royalties Third parties    11.27 % of total Revenue
License Collaborations-Licensing    6.82 % of total Revenue
License Collaborations-Licensing Third parties    6.82 % of total Revenue
License Collaborations-Manufacturing supply    1.65 % of total Revenue
Oncology Immunology segment    57.66 % of total Revenue
Oncology Immunology Third parties    57.58 % of total Revenue
Oncology Immunology Related parties    0.07 % of total Revenue
Oncology Immunology Invoiced Goods-Marketed Products    20.31 % of total Revenue
Oncology Immunology Services-Commercialization of Marketed Products    8.33 % of total Revenue
Oncology Immunology Services-Research and development    0.07 % of total Revenue
Oncology Immunology License Collaborations-Services    9.2 % of total Revenue
Oncology Immunology License Collaborations-Royalties    11.27 % of total Revenue
Oncology Immunology License Collaborations-Licensing    6.82 % of total Revenue
Oncology Immunology License Collaborations-Manufacturing supply    1.65 % of total Revenue
Other Ventures segment    42.34 % of total Revenue
Other Ventures Third parties    41.73 % of total Revenue
Other Ventures Related parties    0.61 % of total Revenue
Other Ventures Invoiced Goods-Distribution    42.34 % of total Revenue
Reportable Oncology Immunology segment    57.66 % of total Revenue
Reportable Oncology Immunology R D    14.57 % of total Revenue
Reportable Oncology Immunology Marketed Products    43.09 % of total Revenue
Reportable Other Ventures segment    42.34 % of total Revenue
PRC    71.79 % of total Revenue
US and others    28.21 % of total Revenue
Customer A    28.21 % of total Revenue
Customer B    13.55 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com